학술논문
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Document Type
Article
Author
Jackson, Graham H ; Davies, Faith E; Pawlyn, Charlotte; Cairns, David A; Striha, Alina; Collett, Corinne; Waterhouse, Anna; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Wilson, Jamie N; Jenner, Matthew W; Cook, Gordon; Kaiser, Martin F; Drayson, Mark T; Owen, Roger G; Russell, Nigel H; Gregory, Walter M; Morgan, Gareth J
Source
In The Lancet Haematology December 2019 6(12):e616-e629
Subject
Language
ISSN
2352-3026